Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) — shareholding pattern, promoter holding, financials and share price
About Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM)
Biofil Chemicals & Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as BIOFILCHEM and on the BSE under scrip code 524396. Its ISIN is INE829A01014.
Incorporated in 1993, Biofil Chemicals and Pharmaceuticals Ltd deals in Pharmaceuticals and Chemicals products. [1]
Biofil Chemicals & Pharmaceuticals Limited (BCPL) primarily manufactures and trades in pharmaceutical products, leveraging two divisions: Pharmaceuticals and Chemicals.
Initially a private company, BCPL transitioned to public status in 1992 and has since expanded into manufacturing a variety of pharmaceutical formulations, including injections and syrups.
Listed peers in Pharmaceuticals: Asston Pharmaceuticals Ltd, Ajooni Biotech Ltd, Vineet Laboratories Ltd, Vasundhara Rasayans Ltd, Bacil Pharma Ltd, Kabra Drugs Ltd.
Valuation & Returns
10 Jul 2026At ₹34.49 a share on 10 Jul 2026, Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) was valued at a price-to-earnings ratio of 20.19x against an industry P/E of 36.41x and a price-to-book of 2.99x on a book value of ₹11.54 per share as of Mar 2025. Solomo computes return on equity of 14.8% and return on capital employed of 17.97% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 20.19x
- Industry P/E
- 36.41x
- P/B
- 2.99x
- EPS (TTM)
- ₹1.71
- Book value / share
- ₹11.54
- ROE
- 14.8%
- ROCE
- 17.97%
- ROA
- 5.46%
- Debt / equity
- 0.03x
- Dividend yield
- 0%
- EBITDA margin
- 13.13%
- 52-week range
- ₹25.6 – ₹48.5
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) reported revenue of ₹28.4 crore, net profit of ₹2.79 crore and earnings per share of ₹1.71. That compares with revenue of ₹33.4 crore and net profit of ₹0.56 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹7.57 crore and net profit ₹0.21 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 22.38 | 30.04 | 40.04 | 33.4 | 28.4 |
| Net profit (₹ cr) | 0.7 | 0.56 | 0.71 | 0.56 | 2.79 |
| EPS (₹) | 0.43 | 0.34 | 0.44 | 0.34 | 1.71 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 10.89% | 2.38% | 14.28% | -16.58% |
| Profit growth | -3.69% | -14.31% | -7.22% | -21.13% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 46.79% of Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0.08%. Market capitalisation was ₹56 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: STARLINE EQUIFIN PRIVATE LIMITED 7.07%, KSL AND INDUSTRIES LIMITED 1.89%, KISHOR HIMMATSINH JHALA 1.22%, GOM INDUSTRIES LTD 1.11%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 46.79% | - | - | 0.08% | 53.21% |
| Mar 2026 | 46.79% | - | - | 0.08% | 53.21% |
| Dec 2025 | 46.79% | - | - | 0.08% | 53.21% |
| Sep 2025 | 46.79% | - | 0% | 0.08% | 53.21% |
| Jun 2025 | 46.82% | - | 0% | 0.08% | 53.18% |
| Mar 2025 | 46.82% | - | 0% | 0.08% | 53.18% |
| Dec 2024 | 46.82% | - | 0% | 0.08% | 53.18% |
| Sep 2024 | 46.82% | - | 0% | 0.08% | 53.18% |